Binder Blunder in CKD.
作者信息
Ix Joachim H
机构信息
Division of Nephrology-Hypertension, University of California San Diego, San Diego, California; Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California; and Division of Preventive Medicine, Department of Family and Preventive Medicine, University of California San Diego, San Diego, California
出版信息
J Am Soc Nephrol. 2020 Nov;31(11):2499-2501. doi: 10.1681/ASN.2020081182. Epub 2020 Sep 11.
Abstract
摘要
相似文献
1
Binder Blunder in CKD.慢性肾脏病中的结合剂失误
J Am Soc Nephrol. 2020 Nov;31(11):2499-2501. doi: 10.1681/ASN.2020081182. Epub 2020 Sep 11.
2
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).KDIGO 美国评论：2017 年 KDIGO 慢性肾脏病-矿物质和骨异常（CKD-MBD）诊治临床实践指南更新。
Am J Kidney Dis. 2017 Dec;70(6):737-751. doi: 10.1053/j.ajkd.2017.07.019. Epub 2017 Sep 21.
3
The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.慢性肾脏病-矿物质和骨异常在慢性肾脏病各阶段的复杂性。
Kidney Int. 2017 Jun;91(6):1436-1446. doi: 10.1016/j.kint.2016.12.029. Epub 2017 Mar 18.
4
[CKD-MBD and cardiovascular disease.].[慢性肾脏病-矿物质和骨异常与心血管疾病。]
Clin Calcium. 2019;29(2):179-184. doi: 10.20837/4201902179.
5
Research on kidney and mineral metabolism in Japan: past, present, and future.日本肾脏与矿物质代谢研究：过去、现在与未来
Clin Exp Nephrol. 2017 Mar;21(Suppl 1):4-8. doi: 10.1007/s10157-016-1366-5. Epub 2016 Dec 22.
6
Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.慢性肾脏病中的甲状旁腺功能：成纤维细胞生长因子23-klotho轴的作用
Contrib Nephrol. 2013;180:110-23. doi: 10.1159/000346791. Epub 2013 May 3.
7
Novel Approaches for Assessment of Bone Turnover in CKD: Is New Always Better?慢性肾脏病中骨转换评估的新方法：新的就一定更好吗？
J Am Soc Nephrol. 2018 Sep;29(9):2443. doi: 10.1681/ASN.2018050561. Epub 2018 Jul 30.
8
The Quest for Better Biomarkers of Bone Turnover in CKD.探寻慢性肾脏病中更好的骨转换生物标志物
J Am Soc Nephrol. 2018 May;29(5):1353-1355. doi: 10.1681/ASN.2018030289. Epub 2018 Apr 12.
9
Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.CKD 患者的骨折：欧洲钙化组织协会和欧洲肾脏协会肾脏病透析与移植分会成员的综述
Kidney Int. 2017 Dec;92(6):1343-1355. doi: 10.1016/j.kint.2017.07.021. Epub 2017 Sep 28.
10
Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.成纤维细胞生长因子-23与慢性肾脏病中的C反应蛋白、血清磷和骨密度相关。
Osteoporos Int. 2010 Nov;21(11):1853-61. doi: 10.1007/s00198-009-1142-4. Epub 2009 Dec 9.
引用本文的文献
1
Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins.肠道螯合剂、吸附剂与肠道源性尿毒症毒素
Toxins (Basel). 2021 Jan 26;13(2):91. doi: 10.3390/toxins13020091.
2
Inflammation: a putative link between phosphate metabolism and cardiovascular disease.炎症：磷酸盐代谢与心血管疾病之间的潜在联系。
Clin Sci (Lond). 2021 Jan 15;135(1):201-227. doi: 10.1042/CS20190895.
本文引用的文献
1
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).一项关于降低 CKD 患者磷酸盐水平对血管终点影响的随机试验（IMPROVE-CKD）。
J Am Soc Nephrol. 2020 Nov;31(11):2653-2666. doi: 10.1681/ASN.2020040411. Epub 2020 Sep 11.
2
A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.柠檬酸铁配位复合物治疗晚期 CKD 的初步随机试验。
J Am Soc Nephrol. 2019 Aug;30(8):1495-1504. doi: 10.1681/ASN.2018101016. Epub 2019 Jul 5.
3
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.烟酰胺和碳酸镧对 CKD 患者血清磷酸盐和纤维母细胞生长因子 23 的影响：COMBINE 试验。
J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13.
4
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability.胃肠道钠/氢交换器 3 的抑制作用可降低 Tenapanor 的细胞旁磷酸盐通透性。
Sci Transl Med. 2018 Aug 29;10(456). doi: 10.1126/scitranslmed.aam6474.
5
Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.美国透析患者中磷结合剂的使用：流行率、成本、证据和政策。
Am J Kidney Dis. 2018 Feb;71(2):246-253. doi: 10.1053/j.ajkd.2017.09.007. Epub 2017 Nov 28.
6
Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study.慢性肾脏病3 - 5期患者饮食中磷摄入量与终末期肾病风险及死亡率的关系：肾脏疾病饮食调整研究
Kidney Int. 2016 Jan;89(1):176-84. doi: 10.1038/ki.2015.284. Epub 2016 Jan 4.
7
Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation.慢性肾脏病中的磷稳态：由美国国家肾脏基金会赞助的科学研讨会报告。
Am J Kidney Dis. 2013 Sep;62(3):457-73. doi: 10.1053/j.ajkd.2013.03.042. Epub 2013 Jun 12.
8
Effect of protein restriction on serum and urine phosphate in the modification of diet in renal disease (MDRD) study.蛋白质限制对肾脏疾病饮食改良研究（MDRD）中血清和尿磷的影响。
Am J Kidney Dis. 2013 Jun;61(6):1045-6. doi: 10.1053/j.ajkd.2013.01.007. Epub 2013 Feb 13.
9
Effects of phosphate binders in moderate CKD.中重度 CKD 患者的磷酸盐结合剂治疗效果。
J Am Soc Nephrol. 2012 Aug;23(8):1407-15. doi: 10.1681/ASN.2012030223. Epub 2012 Jul 19.
10
A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease.针对慢性肾脏病磷代谢的随机试验蓝图。
Kidney Int. 2009 Oct;76(7):705-16. doi: 10.1038/ki.2009.246. Epub 2009 Jul 15.
Zotero 插件